tiprankstipranks
Circio Holding ASA Expands Capital and Advances RNA Therapies
Company Announcements

Circio Holding ASA Expands Capital and Advances RNA Therapies

Targovax ASA (GB:0RIS) has released an update.

Pick the best stocks and maximize your portfolio:

Circio Holding ASA, a biotechnology company, has successfully registered an increase in share capital following the conversion of bonds, bringing its new capital to NOK 15,211,804.20. The company is pioneering RNA therapeutics with its unique circVec platform, which shows promise in treating various diseases. Circio is also advancing its cancer vaccine, TG01, through clinical trials in collaboration with academic and industry partners.

For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskCircio CTO Exercises Warrants Amidst RNA Tech Advances
TipRanks European Auto-Generated NewsdeskCircio Holding ASA Expands Share Capital Amid Therapeutics Focus
TipRanks European Auto-Generated NewsdeskCircio CEO Exercises Warrants Amid Biotech Advancements
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App